<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[케어덱스 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=47423></link><description><![CDATA[케어덱스 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sun, 19 Apr 2026 02:42:32 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2025/02/12_1028147215_20250223105453_5660172546.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[CareDx Announces Study Showing AlloSeq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1006260</link><description><![CDATA[SOUTH SAN FRANCISCO, Calif.--(Business Wire/Korea Newswire)--CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ - a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers - today announced findings published in Transplant International1 that show the performance ...]]></description><pubDate>Sun, 23 Feb 2025 11:15:00 +0900</pubDate></item><item><title><![CDATA[케어덱스, 알로시크 cfDNA의 장기이식 환자 거부반응 감지 정확도가 높다는 연구 결과 발표]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1006261</link><description><![CDATA[브리즈번, 캘리포니아--(Business Wire/뉴스와이어)--이식 환자와 치료인력을 위한 임상적으로 차별화된 고부가가치 의료 솔루션의 발견, 개발, 상용화에 주력하는 선도적 정밀의학 회사이자 이식 전문 기업(The Transplant Company™)인 케어덱스(CareDx, Inc.)(나스닥: CDNA)가 트랜스플랜트 인터내셔널(Transplant International)[1]에 동종이식 거부반응을 감지하는 데 있어 알로시크(AlloSeq™) cfDNA의 성능이 연구소에서 ...]]></description><pubDate>Sun, 23 Feb 2025 11:15:00 +0900</pubDate></item></channel></rss>